Thermo Fisher Scientific (TMO) Financial Analysis & Valuation | Quarter Chart
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instrumen... more
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty di... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $255.13B | Exchange | NYSE |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | US | CEO | Marc N. Casper |
| IPO Date | 1980-03-17 | CAGR | 13.66% |
| Employees | 125,000 | Website | www.thermofisher.com |
| Div. Yield | 0.02% | Payout Ratio | 9% |
| Buy Back Yield | 0.02% | Total Yield | 0.04% |
TMO chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $276.67B | P/E | 29.79 | Forward P/E | 25.01 | PEG | 3.99 |
| P/S | 4184.04 | P/B | 3681.69 | P/CF | 21510.65 | P/FCF | 26536.73 |
| Sales | $46.34B | Sales 1Y | 7.23% | Sales 3Y | 6.46% | Sales 5Y | 21.14% |
| EPS | $23.16 | EPS 1Y | 7.58% | EPS 3Y | 27.15% | EPS 5Y | -13.82% |
| Sales QoQ | 8.99% | EPS QoQ | 5.64% | Sales QoQ Avg | 2.84% | EPS QoQ Avg | 3.11% |
| Gross Margin | 40.37% | Operating Margin | 17.69% | Profit Margin | 15.06% | ROCE | 8.35% |
| ROA | 6% | ROE | 13% | Altman Z Score | 3.35 | Piotroski Score | 6 |
| Current Ratio | 1.55 | Quick Ratio | 1.18 | Cash Ratio | 0.27 | Op. CF Ratio | 0.14 |
| Debt/Equity | 0.81 | Debt/Assets | 0.38 | Lt Debt/Equity | 0.74 | Lt Debt/Cap. | 0.43 |
| Intrst Cov. | 5.59 | Inventory Turnover | 4.91 | Asset Turnover | 0.41 | Receivables Turnover | 4.9 |
| Enterprise Value | $276.67B | P/E Ratio | 29.79 |
| Forward P/E | 25.01 | PEG Ratio | 3.99 |
| P/S Ratio | 4184.04 | P/B Ratio | 3681.69 |
| P/CF Ratio | 21510.65 | P/FCF Ratio | 26536.73 |
| EPS | $23.16 | EPS Growth 1Y | 7.58% |
| EPS Growth 3Y | 27.15% | EPS Growth 5Y | -13.82% |
| Revenue Growth 1Y | 7.23% | Gross Margin | 40.37% |
| Operating Margin | 17.69% | Profit Margin | 15.06% |
| ROE | 13% | ROA | 6% |
| ROCE | 8.35% | Current Ratio | 1.55 |
| Quick Ratio | 1.18 | Cash Ratio | 0.27 |
| Debt/Equity | 0.81 | Interest Coverage | 5.59 |
| Altman Z Score | 3.35 | Piotroski Score | 6 |
Thermo Fisher Scientific (TMO) valuation & financials
Thermo Fisher Scientific (TMO) has a market capitalization of $255.13B and trades at a price-to-earnings ratio of 29.8. It operates in the Healthcare sector (Medical - Diagnostics & Research).
Thermo Fisher Scientific's revenue grew +7.2% over the last year.
Thermo Fisher Scientific's next earnings report is scheduled for October 21, 2026 before market open (provider scheduled date); analysts estimate EPS of $6.41. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)